Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Angiotensin converting enzyme (ACE) inhibitors are a widely used intervention for blood pressure control, and are particularly beneficial in hypertensive type 2 diabetic subjects with insulin resistance. The hemodynamic effects of ACE inhibitors are associated with enhanced levels of the vasodilator bradykinin and decreased production of the vasoconstrictor and growth factor angiotensin II (ATII). In insulin‐resistant conditions, ACE inhibitors can also enhance whole‐body glucose disposal and glucose transport activity in skeletal muscle. This review will focus on the metabolic consequences of ACE inhibition in insulin resistance. At the cellular level, ACE inhibitors acutely enhance glucose uptake in insulin‐resistant skeletal muscle via two mechanisms. One mechanism involves the action of bradykinin, acting through bradykinin B 2 receptors, to increase nitric oxide (NO) production and ultimately enhance glucose transport. A second mechanism involves diminution of the inhibitory effects of ATII, acting through AT 1 receptors, on the skeletal muscle glucose transport system. The acute actions of ACE inhibitors on skeletal muscle glucose transport are associated with upregulation of insulin signaling, including enhanced IRS‐1 tyrosine phosphorylation and phosphatidylinositol‐3‐kinase activity, and ultimately with increased cell‐surface GLUT‐4 glucose transporter protein. Chronic administration of ACE inhibitors or AT 1 antagonists to insulin‐resistant rodents can increase protein expression of GLUT‐4 in skeletal muscle and myocardium. These data support the concept that ACE inhibitors can beneficially modulate glucose control in insulin‐resistant states, possibly through a NO‐dependent effect of bradykinin and/or antagonism of ATII action on skeletal muscle. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295 · cited 1×
“Insulin stimulation of skeletal muscle glucose transport results from the activation of a series of intracellular proteins (reviewed recently by Shepherd and Kahn, 1999; Zierath et al., 2000).”
BackgroundExercise, Glucose Transport, and Insulin Sensitivity
Goodyear, L. J., & Kahn, B. B. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.235 · Cited by 1,056 · cited 1×
“These insulin-independent mechanisms involve an increase in intracellular Ca2þ (see reviews by Holloszy and Hansen, 1996; Goodyear and Kahn, 1998; Ryder et al., 2001) and a role of the activation of 50-adenosinemonophosphate-activated protein kinase (AMP kinase), an enzyme activated by a decrease…”
BackgroundZierath, J. R., He, L., Gumà, A., Wahlström, E. O., Klip, A., & Wallberg-Henriksson, H. (1996) · Diabetologia · doi:10.1007/bf02658504 · Cited by 402
Krook, A., Björnholm, M., Galuska, D., Jiang, X. J., Fahlman, R., Myers, M. G., Wallberg-Henriksson, H., & Zierath, J. R. (2000) · Diabetes · doi:10.2337/diabetes.49.2.284 · Cited by 375 · cited 1×
“Moreover, significantly less insulin stimulation of the insulin receptor and downstream insulin signaling factors, including IRS-1, PI3-kinase, and Akt, occurs in skeletal muscle from insulin-resistant subjects (Goodyear et al., 1995; Björnholm et al., 1997; Krook et al., 1998, 2000).”
BackgroundEnergy-sensing and signaling by AMP-activated protein kinase in skeletal muscle
Winder, W. W. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.3.1017 · Cited by 375
Insulin action and insulin resistance in human skeletal muscle
Zierath, J. R., Krook, A., & Wallberg-Henriksson, H. (2000) · Diabetologia · doi:10.1007/s001250051457 · Cited by 367 · cited 2×
“Insulin stimulation of skeletal muscle glucose transport results from the activation of a series of intracellular proteins (reviewed recently by Shepherd and Kahn, 1999; Zierath et al., 2000).”
BackgroundPedersen, O., Bak, J. F., Andersen, P. H., Lund, S., Moller, D. E., Flier, J. S., & Kahn, B. B. (1990) · Diabetes · doi:10.2337/diab.39.7.865 · Cited by 329
Stimulation of glucose transport in skeletal muscle by hypoxia
Cartee, G. D., Douen, A. G., Ramlal, T., Klip, A., & Holloszy, J. O. (1991) · Journal of Applied Physiology · doi:10.1152/jappl.1991.70.4.1593 · Cited by 305
Kapur, S., Bédard, S., Marcotte, B., Côté, C. H., & Marette, A. (1997) · Diabetes · doi:10.2337/diab.46.11.1691 · Cited by 225 · cited 1×
“Finally, one investigation indicates that the induction of NO in skeletal muscle invitro isassociated witha diminutionof insulinstimulated glucose transport activity (Kapur et al., 1997).”
BackgroundRyder, J. W., Yang, J., Galuska, D., Rincón, J., Björnholm, M., Krook, A., Lund, S., Pedersen, O., Wallberg-Henriksson, H., Zierath, J. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.4.647 · Cited by 216
Exercise-stimulated glucose transport in skeletal muscle is nitric oxide dependent
Roberts, C. K., Barnard, R. J., Scheck, S. H., & Balon, T. W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.1.e220 · Cited by 208 · cited 1×
“…(Young et al., 1997; Young and Leighton, 1998), while in other investigations NO or NO donors activate insulin-independent glucose transport (Balon and Nadler, 1994, 1997; Etgen et al., 1997; Roberts et al., 1997; Young et al., 1997) by upregulation of GLUT-4 translocation (Etgen et al., 1997).”
BackgroundAdditive effect of contractions and insulin on GLUT-4 translocation into the sarcolemma
Gao, J., Ren, J., Gulve, E. A., & Holloszy, J. O. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.77.4.1597 · Cited by 116 · cited 1×
“Like insulin, these factors activated by contraction and hypoxia ultimately signal the translocation of GLUT-4 to the plasma membrane, thereby allowing for an increase in glucose transport (Cartee et al., 1991; Goodyear et al., 1991; Gao et al., 1994).”
Background
Cited by
The metabolic syndrome: role of skeletal muscle metabolism.
Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. (2006) · Annals of Medicine · doi:10.1080/07853890600888413 · Cited by 362
Self-citationOptimal management of sarcopenia
Sumukadas, D. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s11473 · Cited by 303
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
Scheen, A. J. (2004) · Drugs · doi:10.2165/00003495-200464220-00004 · Cited by 293
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70146-5 · Cited by 252
Sumukadas, D., Witham, M. D., Struthers, A. D., & McMurdo, M. E. T. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061339 · Cited by 246
Metadata
- Authors
- Henriksen, E. J., & Jacob, S.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2003-04-23
- Volume
- 196
- Issue
- 1
- Pages
- 171-179
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2076529186
- Cited by
- 132
- References
- 15
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.